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ABSTRACT

The realization that low–glycemic index diets were formulated using resistant starch led to more than a decade of research on the health effects
of resistant starch. Determination of the metabolizable energy of the resistant starch product allowed for the performance of isocaloric studies.
Fermentation of resistant starch in rodent studies results in what appears to be a healthier gut, demonstrated by increased amounts of shortchain fatty acids, an apparent positive change in the microbiota, and increased gene expression for gene products involved in normal healthy
proliferation and apoptosis of potential cancer cells. Additionally, consumption of resistant starch was associated with reduced abdominal fat
and improved insulin sensitivity. Increased serum glucagon-like peptide 1 (GLP-1) likely plays a role in promoting these health benefits. One
rodent study that did not use isocaloric diets demonstrated that the use of resistant starch at 8% of the weight of the diet reduced body fat. This
appears to be approximately equivalent to the human fiber requirement. In human subjects, insulin sensitivity is increased with the feeding of
resistant starch. However, only 1 of several studies reports an increase in serum GLP-1 associated with resistant starch added to the diet. This
means that other mechanisms, such as increased intestinal gluconeogenesis or increased adiponectin, may be involved in the promotion of
improved insulin sensitivity. Future research may confirm that there will be improved health if human individuals consume the requirement for
dietary fiber and a large amount of the fiber is fermentable. Adv Nutr 2015;6:198–205.
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Beginning of Resistant Starch Research at the
Louisiana State University Agricultural Center
In the 2002, a member of our research group attended a research presentation by Dr. Jennifer Brand-Miller at the Experimental Biology meeting on how low-glycemic diets reduced
body fat fairly dramatically in rodents (1). For several years,
we tried to reduce body fat in genetic models of obesity,

such as the Zucker obese rats, with very limited success (2).
Thus, effects of low-glycemic diets were very impressive, although at that time the research did not include Zucker obese
rats. Our research group planned to conduct some similar
studies and contacted Dr. Brand-Miller, who informed us
that, to lower the glycemic load of her rodent diets, she
used resistant starch (RS)12 (1). At that point, our group decided to focus our laboratory research on RS.
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Current State of Knowledge
RSs are broadly characterized into 4 categories: RS1–RS4 (3,
4). RS1 is found in whole grains (WGs) and legumes and is
entrapped in a nondigestible matrix. Ungelatinized starch
granules are found in foods such as raw potatoes and highamylose cornstarch and comprise the RS2 category. The RS3
category includes foods that have undergone “retrogradation,”
12

Abbreviations used: GLP-1, glucagon-like peptide 1; HAMRS2, high-amylose maize resistant
starch type 2; PYY, peptide YY; RS, resistant starch; WG, whole grain; ZDF, Zucker diabetic
fatty.
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Role of Resistant Starch in Improving Gut Health,
Adiposity, and Insulin Resistance1–4

Overview of Research Design and Deﬁning RS
In our research, we used proof-of-concept, mechanistic
studies generally using RS at ~23–28% of the weight of
the diet. However, we did perform 2 dose–response studies
using 0%, 18%, and 36%, and 0%, 15%, and 28% of the
diet. Our group used an AIN-recommended semipurified
diet formulated in 1993 (9) as a base and substituted 1 carbohydrate starch source for another as the source of dietary
carbohydrate starch. In our control diets, we used a 100%
amylopectin corn starch (Amioca starch; Ingredion) that is
essentially 100% digestible. To investigate the effects of dietary RS, our group replaced the 100% amylopectin starch
with a corn starch that is ~60% amylose and ~40% amylopectin (Hi-maize 260 resistant starch; Ingredion). Generally,
corn starch that can be bought in the supermarket is ~80%
amylopectin and 20% amylose. Thus, the Hi-maize product
is considered a high-amylose maize starch. This Hi-maize
product also assays as ~50% RS using the modified Englyst
assay (6). The other ~50% of the starch consists of rapidly
digestible starch and slowly digestible starch. Rapidly digestible starch can be digested to glucose within 20 min after initiation of treatment of the high-amylose maize starch with
amylase and other enzymes in an in vitro assay. Slowly digestible starch is digested to glucose within 20–120 min.

RS is any of the starch that is digested after 120 min. It is important to note that there is another commercial assay that is
harsher than the Englyst assay and gives lower values of RS
for samples (Megazyme International), and there is some
debate about which assay is the best for measuring RS.

Fermentation of RS Leading to Improved Gut
Health
Our group performed targeted analysis of the microbiota using culture and qPCR-based methodologies to measure bacteria in bacterial genera that initially ferment the starch
granule and then produce lactate and acetate, which in
turn are converted by bacteria in other bacterial genera to
butyrate (10). Additionally, a global view of the microbiota
using 454 pyrosequencing of bacterial DNA was performed
(11). The targeted bacterial measurements were conducted
using the cecal contents from ovariectomized and sham
rats. We found increased amounts of Lactobacillus species,
Bifidobacterium species, species in Clostridial clusters IV
and XIVa + b, and an increase in the bacterial domain (total
bacteria using universal primers) in sham and ovariectomized rats fed HAMRS2. Elderly (aged 20 mo) C57BL/6J
(black 6) mice were used for the global measurement of
the microbiota. In general, with the global analysis, the phylum
Firmicutes was reduced with increasing doses of HAMRS2,
and Bacteroidetes was increased. However, bacterial species
in Allobaculum genera in Firmicutes were increased. Thus,
the biodiversity of Firmicutes declined because of the fermentation of HAMRS2 in the diet. Surprisingly, bacteria
in Clostridial clusters IV and XIVa + b were reduced with
HAMRS2 feeding, but this was in a different model than the
female rats described above (10). The genus Bifidobacteria increased within the phylum Actinobacteria, and Akkermansia
muciniphila increased in the phylum Verrucomicrobia. These
bacterial changes in mice fed HAMRS2 were correlated positively with measurements of fermentation.
Initially, our studies were limited to gene expression measurement of 2 well-known hormones produced by the gastrointestinal tract peptide YY (PYY) and glucagon-like
peptide 1 (GLP-1). Both the PYY and proglucagon (gene
for GLP-1) genes were increased with HAMRS2 feeding
(7, 8). Along with the increased amounts of gene expression,
the amounts of these hormones in the blood were also increased. GLP-1 and PYY are considered as satiety hormones
(12), but rodents fed HAMRS2 tend to consume more food
than control rodents. Our group demonstrated that GLP-1
with HAMRS2 feeding is elevated persistently over a 24-h
period because of the continual fermentation of HAMRS2
rather than peaking after a meal and dropping between
meals without HAMRS2 feeding (13). These chronically
higher plasma amounts appear not to produce satiety. Primary culture of colonocytes demonstrated that SCFAs in
the media increased expression of PYY and proglucagon
genes, thus linking fermentation products with the production of these gastrointestinal tract hormones (13).
Later, our group performed a gene array for cecal cells to
determine a more global approach on what gene expression
Resistant starch improves health 199
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which occurs when foods containing starches are cooked and
then cooled. Examples of foods in this category include potatoes cooled after cooking and puddings. Chemically modifying
starches with the addition of ester and ether groups and crosslinking amylose strands usually render them resistant to digestion. These starches are found in breads and cakes, and they
are categorized as RS4. Much of the research with RS uses
high-amylose products. The term “resistant starch” was first
used by Englyst et al. (5), as “a small fraction of starch that
was resistant to hydrolysis by exhaustive amylase and pullulanase treatment in vitro.” His group later confirmed that this
same type of starch also resisted hydrolysis in vivo using
healthy ileosteomy subjects (6). Thus, RS is defined as the
amount of starch that reaches the large intestine. Note that
the FDA does not allow the term “resistant starch” on food labels; Hi-maize 260, a purified RS product (Ingredion), is assayed for fiber content, and that amount can be placed on
the food label. This product is often referred to as high-amylose
maize resistant starch type 2 (HAMRS2).
RS, by deﬁnition, is starch that reaches the large intestine
in which it is fermented by bacteria. Therefore, RS is a type
of fermentable ﬁber and could be considered 1 type of prebiotic, i.e., provides “food” for bacteria living in the large intestine. Fermentation of RS results in production of SCFAs
and a reduction in pH in the proximal large intestine. In
the rodent, the cecum is more distinct than in humans,
and generally cecal contents are analyzed for fermentation
products and pH. Additionally, the weight of the cecal contents and empty cecum increase in response to fermentation
(7, 8). HAMRS2 feeding also dramatically changes the composition of the microbiota that inhabits the cecum and the
gene expression of the cecal cells.
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Solute carrier 16a1 transports SCFAs (32, 33). Butyrate is
the main energy source for the cells that line the colon
(34) and is implicated in colon cancer prevention because
it has the “potential to act on secondary chemoprevention
by slowing growth and activating apoptosis in colon cancer
cells” (35). Thus, increased uptake of SCFAs should improve
the health of the gut.

Effects of HAMRS2 on Phenotype
Body fat
Initially, our research group did not know the metabolizable energy of the Hi-maize product, and we simply replaced Amioca control cornstarch with Hi-maize. The more
HAMRS2 we used and the longer the study, the greater the
reduction in abdominal fat (36). Later, we performed a study
using collection cages and bomb calorimetry to determine the
metabolizable energy of the Hi-maize product (37, 38). Our
group teamed with a laboratory in Holland that used another
technique: gain of dry body weight gain on the basal diet with
0–5 g of glucose added compared with dry body weight gain
in rats fed different types of starches (37). The value measured
with both techniques was ~2.8 kcal/g. Once we knew the metabolizable energy for the Hi-maize product, we were able to
design studies with control and test groups fed isocaloric
diets. To produce isocaloric diets, cellulose was added to the
control diet because the product containing HAMRS2 has a
lower metabolizable energy than the control amylopectin
cornstarch, and purified cellulose provides 0 kcal/g because
it is not fermented in rodents (39). Our initial studies without
isocaloric diets were actually testing 2 effects of adding
HAMRS2 to the diet: 1) dilution of dietary metabolizable energy; and 2) fermentation and production of fermentation
products. Using a fermentable fiber/prebiotic in the diet not
only lowers the energy of the diet, as with a nonfermentable
fiber, but also affects the gut microbiota as a result of fermentation products produced by the bacteria. Both the microbiota and the fermentation products affect the health of the
host, such as the behavior of the host through the endocrine,
immune, and nervous systems (40). Using isocaloric diets,
which allowed our group to test the effects of fermentation
on abdominal fat amounts, also resulted in reduced abdominal fat. Our research group previously published these results. The results included reduced abdominal fat in male
C57BL/6J mice (41), male Sprague-Dawley rats (7, 42, 43), female Goto-Kakizaki rats (44), and female ovariectomized and
sham-surgery rats (10). The fat pads excised for measurement
of their weights were epididymal (male) or ovarian (female)
and perirenal (associated with the kidneys) and retroperitoneal (the remaining fat on both the left and right sides of
the abdominal cavity).
The mechanism for this reduction in abdominal fat appears to be an increase in energy expenditure and increased
oxidation of fat (41). C57BL/6J mice, placed in indirect calorimetry cages, demonstrated a signiﬁcant (P < 0.05) reduction in the respiratory quotient (also called respiratory
exchange ratio), and their heat production increased during
the dark cycle (approached significance, P = 0.07). This
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is increased (14). Overall, we observed increases in >2000
genes and specifically in genes associated with cell growth,
proliferation, differentiation, and apoptosis, all likely tied
in a complex manner to improved gut health. For example,
our results included increased gene expression for galactose4-epimerase, which catalyzes the formation of UDP-Nacetylgalactosamine from UDP-N-acetylglucosamine and
represents the first committed step in mucin biosynthesis
(15). The gut plays a major role in detoxifying agents from
food and microbes. After the ingestion of HAMRS2, gut flora
induces the chemopreventive enzyme glutathione transferase
gene (16) expression in the colon of the rat (14). Our group
found that HAMRS2 feeding was associated with a 3-fold elevation of the glutathione S-transferase A5 subunit and a 10fold increase in the glutathione S-transferase Yc2 subunit.
The most upregulated gene in the gene array was dualspecificity protein phosphatase, which responds to environmental stress and prevents oncogenesis (17). Adrenomedullin
was also upregulated (5-fold), and the protein in the blood is
reported to counteract the oxidative stress that leads to insulin
resistance (18).
Many other genes involved with gut health were upregulated in our gene-array study (14). Muscle and microspikes
rat sarcoma (RAS) is involved in the reorganization of the
cytoskeleton of cells (19). Bone morphogenetic factors 2
and 3 genes are important for tissue architecture (20). Hypoxia inducible factor 1, a subunit (21) and vascular endothelial growth factor A (22) are genes important for blood
flow in tissues. Amphiregulin promotes the growth of normal epithelial cells (23) and inhibits the growth of some cancerous cell lines (24) but was also reported to be increased in
association with some tumors. The use of HAMRS2 appears
to promote the beneficial effect of amphiregulin. Le Leu
et al. (25) reported that HAMRS2 promotes apoptosis of
precancerous cells but does not reduce cell proliferation of
healthy cells. Cyclin-dependent kinase inhibitor 1A promotes apoptosis of potentially proinflammatory cells (26).
Several TNF receptors were increased, and, during binding
of TNF proteins to TNF receptors, 1 of 3 pathways can be
stimulated based on cell type and conditions (27, 28).
TNF can be involved in either promoting or preventing apoptosis and stimulating the immune response. Ras homolog
gene family, member B inhibits NF-kB, leading to the promotion of apoptosis of damaged cells (29). NF-kB increases
the protein cellular myc, which represses gene expression of
growth arrest and DNA damage–inducible a and b. The result is the escape from programmed cell death (30). NF-kB
inhibitor b binds to NF-kB, leading to increased apoptosis.
Several of the growth arrest and DNA damage–inducible a
and b proteins promote apoptosis by activating MAPK kinase, which then increases MAPK kinase 4 and then phosphorylation of c-Jun N-terminal kinase (30). Growth arrest
and DNA damage–inducible a and b increases when NF-kB
is inhibited. Neurotensin, a hormone that regulates gut motility, is also increased (31).
Several solute carrier 16 family genes were upregulated.
These are also known as monocarboxylate transporters.

Insulin resistance/sensitivity
In rodent studies, diets containing HAMRS2 improved insulin sensitivity measured with a glucose tolerance test in mice
made partially diabetic with a streptozotocin injection but
had no effect on normal mice (13). Our group then investigated the effects of HAMRS2 in a lean model of type 2 diabetes, the Goto-Kakizaki rat (44). Inclusion of HAMRS2 in
the diet of Goto-Kakizaki rats improved insulin sensitivity
and increased pancreatic mass compared with control rats.

In human subjects, the effects of HAMRS2 on insulin
sensitivity were well documented by the Robertson laboratory in the United Kingdom (48–50) and by Maki et al.
(51). The Robertson laboratory group did not observe an increase in the incretin hormone GLP-1 in humans in their
studies despite its increase in many animal species with
HAMRS2 treatment (7, 8, 13, 43, 44, 52, 53). However, in
their most recent study, they observed increased serum
GLP-1 (54). Two questions from their research include the
following: 1) why is there no GLP-1 response in many humans in several of their studies?; and 2) what is the mechanism for improved insulin sensitivity in humans with
HAMRS2 feeding who did not produce increased GLP-1?
The answer to the first question appears to be that some
individuals produce a defective transcription factor that
normally interacts with the promoter region of the
proglucagon gene in the intestinal L endocrine cells, and
the result is lower production of the proglucagon gene transcript and lower amounts of the protein products that include GLP-1 (55). These individuals have a much greater
risk of type 2 diabetes and have a polymorphism in the
T cell factor 7 lymphoid enhancer-binding factor 2. The answer to the second question is unknown, but 1 possible reason for improved insulin sensitivity may be increased
intestinal gluconeogenesis (56). Recently, De Vadder et al.
(56) reported increased insulin sensitivity in mice fed fructooligosaccharide, butyrate, or propionate. The glucose produced by intestinal gluconeogenesis binds to receptors in the
portal vein, and this signals the brain to inform the liver to
reduce hepatic gluconeogenesis. Butyrate binds to its receptor in the intestinal cells and signals to the brain through a
cAMP mechanism. Propionate is a substrate for gluconeogenesis, and its binding to its receptor also signals to the
brain. Using knockout mice for glucose-6-phosphatase prevented the effects on insulin sensitivity. Intraperitoneal
treatment with capsaicin, presumably damaging nerves
from the portal vein, also knocked out the insulin sensitivity
associated with fructooligosaccharide, butyrate, or propionate. However, when our group used intraperitoneal capsaicin to destroy nonmylenated neurons in the gut, we still
observed beneficial health effects of HAMRS2 (43). Thus,
there may be other unknown mechanisms that cause the
increased insulin sensitivity in individuals given dietary
HAMRS2 that do not produce an increase in serum GLP1. Our group also showed that mice fed HAMRS2 had increased serum amounts of adiponectin (57), which may
also be another possible mechanism for increased insulin
sensitivity in human subjects.
WG RS
Other forms of RS besides HAMRS2 were also reported to
have beneﬁcial health effects if consumed. For example,
RS4 was reported to prevent high-fat diet–induced obesity
(45). Currently, there is much interest in WGs for their potential health benefits (58). Epidemiologic studies demonstrated beneficial health effects, such as improved satiety,
blood cholesterol concentrations, and bowel functioning
Resistant starch improves health 201
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means that rodents fed HAMRS2 had increased fat oxidation
and also may have increased energy expenditure. No effect
was observed on physical activity, indicating that energy metabolism, and particularly oxidation of fat, was increased.
Similarly, Shimotoyodome et al. (45) used the chemically
modified version of RS, RS4, in C57BL/6J mice to prevent
high-fat diet–induced obesity by increasing FA oxidation
in the liver. So et al. (46) also demonstrated results similar
to those of our research group using HAMRS2. Mice fed
HAMRS2 had similar body weights but lower percentages of
body obesity (subcutaneous and visceral), intrahepatocellular
lipids, plasma leptin, plasma adiponectin, and plasma insulin/glucose than mice fed readily digestible starch. Additionally, adipocytes from epidiymal fat pads were smaller in
mice fed HAMRS2 but had greater insulin-stimulated glucose
uptake. The latter indicates greater insulin sensitivity. One major difference between the study by our research group and the
study by So et al. (46) is that our studies demonstrated reduced
body fat with HAMRS2 feeding compared with a control diet
that had an equivalent energy content as the HAMRS2 diet.
However, the diet with HAMRS2 in their study had a lower
energy density (10 kJ/g) than the diet with readily digestible
starch (15 kJ/g). With isocaloric diets, rodents fed HAMRS2
usually have numerically greater amounts of food and energy
intake (P $0.05), but it is not a statistically significant difference. In the study by So et al. (46), the mice fed HAMRS2 consumed significantly greater amounts of food but had lower
energy intake. They argued that this lower energy intake was
the result of greater neuronal activity in regions of the hypothalamus involved in appetite regulation.
Belobrajdic et al. (47) reported a dose–response study in
obese-prone Sprague-Dawley rats. The results showed that addition of HAMRS2 to the diet reduced body fat when
HAMRS2 was added at 8% of the weight of the diet but not
at 4%. The researchers did not feed isocaloric diets, and,
thus, the effect on the obese-prone rats is because of both reduction of the dietary energy of the diet containing HAMRS2
and fermentation of HAMRS2. This is essentially what would
occur with humans if they added a source of HAMRS2 to their
diets. These results are encouraging because of the possibility
of reducing body fat in humans who consume adequate
amounts of fermentable fiber. The estimated value for rodents
was 10% of the weight of the diet (G Fahey, University of Illinois-Urbana, personal communication). Therefore, the use of
products containing RS would appear to reduce body fat in
humans who meet their dietary fiber requirement that includes a substantial amount of fermentable fiber.

FIGURE 1 A schematic
summary of the beneficial gut
health effects of a microbiota
in response to the feeding of a
high-fat diet vs. a gut
microbiota in response to the
feeding of RS or a whole-grain
RS product. The former
reduces and the latter
increases beneficial health
effects. RS, resistant starch;
WGRS, whole-grain resistant
starch.

202 Keenan et al.

thought that this type of rat may be a nonresponder to
HAMRS2. Most of the studies by our group that used
HAMRS2 also used Sprague-Dawley rats. In these studies,
our group usually observed soft feces during the study with
fermentation of HAMRS2. Additionally, effects of fermentation were significantly greater in rats fed the WG products.
This is likely because of components beyond HAMRS2 found
in the 2 WG flour–containing diets. As stated above, the WG
diets would also have RS1 (3, 4), arabinoxylans (61), cellulose
and hemicellulose (59), and polyphenolic (59) compounds.
The latter 4 types of compounds would be found in the
bran component of the WG (59).
High-fat diets impair the fermentation response
High-fat diets modify negatively the intestinal microbiota
and impair gut health compared with low-fat diets (63, 64).
Our laboratory demonstrated healthy fermentation in rodents using low-fat (18% of energy) diets (7, 10, 41–44). Because moderate-fat diets (~30% of energy) are recommended
for good health and a palatable diet (65), characterization of
the effects of moderate-fat diets is important to determine
whether changes to the intestinal microbiota [such as an increase in the genus Allobaculum of the phylum Firmicutes and
the genus Akkermansia of the phylum Verrucomicrobiota (64)]
also occur. Very little is known about a moderate-fat diet. Our
group demonstrated that fermentation and other beneficial
health effects of HAMRS2 feeding are attenuated with the consumption of a high-fat (42% of energy) diet (42). Another
study reported similar results in rats with the use of high
fats with fermentable fiber in the form of pectin, guar gum,
or a mixture of both (66). The researchers found that the
high-fat diet reduced the formation of butyrate and increased
succinate, inflammation, liver fat, and cholesterol. The dietary
fiber only partially counteracted these negative effects.
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with higher intake of WGs (58, 59). WG products contain a
variety of compounds, including, but not limited to, RS1 (60)
and other fermentable (e.g., arabinoxylans and oligosaccharides) and nonfermentable (e.g., cellulose and hemicellulose)
fibers (61). The effect of RS1 may be difficult to investigate
without the confounding by the many other components in
WG products. Additionally, purification of RS1 may destroy
the WG structure, such as the cell-wall structure that is
needed to make the starch in the WG kernel resistant to digestion (62). Our research group recently completed a study using Zucker diabetic fatty (ZDF) rats (F Goldsmith, J Guice,
R Page, AM Raggio, RW Stout, A Gaither, R Elzer, C Pelkman,
J Ye, J Finley, RJ Martin, J Geaghan, H Durham, D Coulon,
MJ Keenan, unpublished data, 2012). Four dietary groups
were used. The first group was an isolated starch control using
the 100% amylopectin Amioca product for the starch in an
AIN-recommended diet formulated in 1993 for mature rodents. For the second group, the isolated Hi-maize starch product was used to provide HAMRS2. However, a WG version
of the Hi-maize product was also used in the third group, and
WG dent corn was used for a WG control group. Dent corn is
typical corn with ~80% amylopectin and ~20% amylose and
would have RS1 in the WG component and a small amount of
HAMRS2 in the amylose fraction. The WG version of Himaize would have RS1 and a high amount of HAMRS2. Amylopectin starch was replaced with varying amounts of 1 of
the 3 other products to result in 4 diets with 0%, 25%,
25%, and 6.9% RS by weight of the diets. Although there
were no phenotypic changes observed, the ZDF rats robustly
fermented the RS in the 3 diets that contained it. This was
demonstrated by lower pH of the cecal contents, increased cecum weights, and increased amounts of SCFAs in the cecal
contents. One interesting finding was that, during the study,
the ZDF rats did not have soft or loose stools, and it was

Summary
Many studies were performed with RS fed to animal models
and demonstrated many health beneﬁts, including increased
fermentation leading to improved gut health, reduced adiposity, and improvement in insulin sensitivity. The major
beneﬁcial result observed in studies with human subjects
is an increase in insulin sensitivity. Most animal studies
demonstrate an increase in the gastrointestinal tract incretin
hormone GLP-1, but only 1 of the studies demonstrating
improved insulin sensitivity reported an increase in serum

GLP-1. This may be because many humans who develop insulin resistance and type 2 diabetes have an ineffective allele
for a transcription factor that is known to interact with the
promoter region of the proglucagon gene and to increase its
transcription. The mechanism for improved insulin sensitivity in human subjects in those who do not produce increased amounts of GLP-1 with HAMRS2 feeding is
unknown at this time but likely would involve positive
changes in the microbiota. Also, very encouraging is the
study in obese-prone rats that observed reduced body fat
with 8% of the weight of the diet as HAMRS2. This result
may mean that humans could reduce body fat if the recommended amounts of dietary ﬁber are consumed, including a
variety of fermentable ﬁbers.
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Reduction of metabolic endotoxemia
Metabolic endotoxemia is a relatively new concept based on
recent evidence that certain gram-negative bacteria enhance
the exposure to the LPSs (67–69). LPSs are large glycolipids
derived from the outer membrane of gram-negative bacteria. High-fat diets promote a dysbiosis in the microbiota
and a “leaky gut,” allowing LPSs to enter the blood (67,
70). LPSs cause a condition of “metabolic endotoxemia”
characterized by low-grade inflammation and insulin resistance. The LPSs are powerful stimulators of the innate
immune system response. After binding to the toll-like
receptor 4 and its coreceptors, LPSs trigger a cascade of responses, ultimately resulting in the release of proinflammatory molecules that interfere with the utilization of glucose
metabolism and insulin sensitivity. Furthermore, a selective
increase of Bifidobacteria in the gut improves high-fat diet–
induced diabetes in mice through a mechanism associated
with decreased endotoxemia (67). We showed that a diet
with HAMRS2 increases gut Bifidobacteria and improves insulin sensitivity in the Goto-Kakizaki rat, an animal model
of diabetes (44). In this study, LPSs were not measured,
but other studies demonstrated that the use of the nonsystemic antibiotics neomycin and ampicillin cured a dysbiosis
in obese mice and mice fed a high-fat diet (70). This resulted
in lower plasma LPS concentration. Possibly, dietary manipulation of gut microbes could be a potent strategy for the
control of metabolic diseases, as well.
Bifidobacteria may be too simple to be the only answer for
a healthy gut. The genus Akkermansia was only discovered 9 y
ago, and bacteria in this genus, particularly Akkermansia mucinophila, degrade mucin (71). Mucin serves as the carbon
and nitrogen source for bacteria in this genus. They degrade
N-glycans, and the gene-array study by our group (14) demonstrated that galactose-4-epimerase, which catalyzes the
formation of UDP-N-acetylgalactosamine from UDP-Nacetylglucosamine and represents the first committed step
in mucin biosynthesis (72), was upregulated. This enzyme
transfers an N-glycan to the oxygen of serines or threonines
to produce O-glycans. These O-glycans promote the growth
of favorable bacteria in the large intestine. Akkermansia is
also 1 of the genera increased in mice fed a low-fat diet vs.
a high-fat diet (64). With the increase of the study of the microbiome in recent years, other newly discovered genera of
bacteria may be increased when investigating the interaction
among 3 bioactive dietary components: 1) moderate fat; 2)
RS; and 3) WG (Figure 1).
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